Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Selank | SS-31 (Elamipretide) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 250-500 mcg daily via intranasal administration (0.15% solution, 2-3 drops per nostril). | Research indicates 0.05-0.25 mg/kg daily via subcutaneous injection. Clinical trials used 4-40 mg/day IV or SC. |
| Timing | Can be dosed morning through evening. Unlike Semax, Selank is calming and can be used at night. | Morning dosing preferred. No food timing restrictions. |
| Cycle Duration | 14-21 day cycles with equal rest periods. | Clinical trials ranged from single dose to 48 weeks. Optimal cycle length not established. |
| Evidence Level | moderate_human | Emerging (Phase 2/3 trials) |
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide analog of the immunomodulatory peptide tuftsin (from IgG heavy chain) with a Pro-Gly-Pro extension for metabolic stability. It allosterically modulates GABA-A receptors, enhancing GABA binding and GABAergic neurotransmission. Selank modifies mRNA levels of 84 genes involved in GABAergic neurotransmission in the frontal cortex, enhances enkephalinase inhibition (increasing endogenous enkephalin levels), and modulates serotonergic and noradrenergic systems to produce anxiolytic and nootropic effects.
Research indicates 250-500 mcg daily via intranasal administration (0.15% solution, 2-3 drops per nostril).
Can be dosed morning through evening. Unlike Semax, Selank is calming and can be used at night.
14-21 day cycles with equal rest periods.
SS-31 (D-Arg-Dmt-Lys-Phe-NH2, also known as elamipretide/Bendavia) is a cell-permeable tetrapeptide that localizes to the inner mitochondrial membrane and binds cardiolipin via electrostatic interactions. This stabilizes cardiolipin against oxidative damage, preserving cristae integrity, reducing ROS production, and maintaining mitochondrial ATP production. SS-31 interacts with proteins in two functional groups: oxidative phosphorylation complexes and 2-oxoglutarate metabolic enzymes — all known cardiolipin binders. It restores mitochondrial function without acting as a direct antioxidant.
Research indicates 0.05-0.25 mg/kg daily via subcutaneous injection. Clinical trials used 4-40 mg/day IV or SC.
Morning dosing preferred. No food timing restrictions.
Clinical trials ranged from single dose to 48 weeks. Optimal cycle length not established.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →